Cargando…

Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells

SIMPLE SUMMARY: Estrogen receptor α (ERα) is a key driver and clinical target in breast cancer, with ~75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies (tamoxifen and aromatase inhibitors) targeting ERα are the preferred treatment for ER+/HER2− breast tumors due to their effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Muluhngwi, Penn, Klinge, Carolyn M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307416/
https://www.ncbi.nlm.nih.gov/pubmed/34298743
http://dx.doi.org/10.3390/cancers13143530
_version_ 1783728041296396288
author Muluhngwi, Penn
Klinge, Carolyn M.
author_facet Muluhngwi, Penn
Klinge, Carolyn M.
author_sort Muluhngwi, Penn
collection PubMed
description SIMPLE SUMMARY: Estrogen receptor α (ERα) is a key driver and clinical target in breast cancer, with ~75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies (tamoxifen and aromatase inhibitors) targeting ERα are the preferred treatment for ER+/HER2− breast tumors due to their efficacy and tolerance in most patients. However, patients develop resistance to these endocrine therapies and disease progression to metastasis remains a major clinical problem. There are multiple mechanisms involved in the progression to endocrine resistance, including epigenetic changes in non-coding RNAs that regulate cellular pathways leading to cancer progression and metastasis. This paper summarizes the role of long non-coding RNAs regulated by miR-29 in endocrine-resistant breast cancer. ABSTRACT: Despite improvements in the treatment of endocrine-resistant metastatic disease using combination therapies in patients with estrogen receptor α (ERα) primary tumors, the mechanisms underlying endocrine resistance remain to be elucidated. Non-coding RNAs (ncRNAs), including microRNAs (miRNA) and long non-coding RNAs (lncRNA), are targets and regulators of cell signaling pathways and their exosomal transport may contribute to metastasis. Previous studies have shown that a low expression of miR-29a-3p and miR-29b-3p is associated with lower overall breast cancer survival before 150 mos. Transient, modest overexpression of miR-29b1-3p or miR-29a-3p inhibited MCF-7 tamoxifen-sensitive and LCC9 tamoxifen-resistant cell proliferation. Here, we identify miR-29b-1/a-regulated and non-regulated differentially expressed lncRNAs in MCF-7 and LCC9 cells using next-generation RNA seq. More lncRNAs were miR-29b-1/a-regulated in LCC9 cells than in MCF-7 cells, including DANCR, GAS5, DSCAM-AS1, SNHG5, and CRND. We examined the roles of miR-29-regulated and differentially expressed lncRNAs in endocrine-resistant breast cancer, including putative and proven targets and expression patterns in survival analysis using the KM Plotter and TCGA databases. This study provides new insights into lncRNAs in endocrine-resistant breast cancer.
format Online
Article
Text
id pubmed-8307416
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83074162021-07-25 Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells Muluhngwi, Penn Klinge, Carolyn M. Cancers (Basel) Article SIMPLE SUMMARY: Estrogen receptor α (ERα) is a key driver and clinical target in breast cancer, with ~75% of women having ERα+ breast tumors at diagnosis. Endocrine therapies (tamoxifen and aromatase inhibitors) targeting ERα are the preferred treatment for ER+/HER2− breast tumors due to their efficacy and tolerance in most patients. However, patients develop resistance to these endocrine therapies and disease progression to metastasis remains a major clinical problem. There are multiple mechanisms involved in the progression to endocrine resistance, including epigenetic changes in non-coding RNAs that regulate cellular pathways leading to cancer progression and metastasis. This paper summarizes the role of long non-coding RNAs regulated by miR-29 in endocrine-resistant breast cancer. ABSTRACT: Despite improvements in the treatment of endocrine-resistant metastatic disease using combination therapies in patients with estrogen receptor α (ERα) primary tumors, the mechanisms underlying endocrine resistance remain to be elucidated. Non-coding RNAs (ncRNAs), including microRNAs (miRNA) and long non-coding RNAs (lncRNA), are targets and regulators of cell signaling pathways and their exosomal transport may contribute to metastasis. Previous studies have shown that a low expression of miR-29a-3p and miR-29b-3p is associated with lower overall breast cancer survival before 150 mos. Transient, modest overexpression of miR-29b1-3p or miR-29a-3p inhibited MCF-7 tamoxifen-sensitive and LCC9 tamoxifen-resistant cell proliferation. Here, we identify miR-29b-1/a-regulated and non-regulated differentially expressed lncRNAs in MCF-7 and LCC9 cells using next-generation RNA seq. More lncRNAs were miR-29b-1/a-regulated in LCC9 cells than in MCF-7 cells, including DANCR, GAS5, DSCAM-AS1, SNHG5, and CRND. We examined the roles of miR-29-regulated and differentially expressed lncRNAs in endocrine-resistant breast cancer, including putative and proven targets and expression patterns in survival analysis using the KM Plotter and TCGA databases. This study provides new insights into lncRNAs in endocrine-resistant breast cancer. MDPI 2021-07-14 /pmc/articles/PMC8307416/ /pubmed/34298743 http://dx.doi.org/10.3390/cancers13143530 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Muluhngwi, Penn
Klinge, Carolyn M.
Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
title Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
title_full Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
title_fullStr Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
title_full_unstemmed Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
title_short Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells
title_sort identification and roles of mir-29b-1-3p and mir29a-3p-regulated and non-regulated lncrnas in endocrine-sensitive and resistant breast cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307416/
https://www.ncbi.nlm.nih.gov/pubmed/34298743
http://dx.doi.org/10.3390/cancers13143530
work_keys_str_mv AT muluhngwipenn identificationandrolesofmir29b13pandmir29a3pregulatedandnonregulatedlncrnasinendocrinesensitiveandresistantbreastcancercells
AT klingecarolynm identificationandrolesofmir29b13pandmir29a3pregulatedandnonregulatedlncrnasinendocrinesensitiveandresistantbreastcancercells